THERAPY DOSSIER · th-13ed56dc7f58

Aurothioglucose (ATG)

Drug · Thioredoxin reductase 1 inhibitor (INHIBITOR; direct interaction; IC50 = 65 nM)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Thioredoxin reductase 1 inhibitor (INHIBITOR; direct interaction; IC50 = 65 nM)
Target: CHEMBL1927 (thioredoxin reductase 1)
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: 1940
Development stage: Not recorded
ChEMBL record: CHEMBL1697725 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: (1-thio-d-glucopyranosato)gold; Aureotan; Aurothioglucose; Aurumine; Authron; Brenol; Glysanol B; NSC-759601; Oronol; Solganal B
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24295151 ↗2014Reported benefit

The thioredoxin reductase-1 inhibitor aurothioglucose attenuates lung injury and improves survival in a murine model of acute respiratory distress syndrome.

MouseEndotoxin/LPSintraperitoneal25 mg/kg12 h after intratracheal LPS, before hyperoxia exposure

Model: Acute respiratory distress syndrome induced by a single intratracheal dose of lipopolysaccharide (0.375 microg/g) followed by exposure to hyperoxia (>95% O2)

Aurothioglucose significantly attenuated LPS plus hyperoxia induced lung injury, increased lung GCLM expression and glutathione levels, and decreased mortality. Glutathione depletion completely prevented the protective effects, indicating the benefit is glutathione dependent.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…